Cell‐assembled nanoclusters of MSC‐targeting Gd‐DOTA‐peptide as a T2 contrast agent for MRI cell tracking. (27th March 2018)

• Record Type: Journal Article
• Authors: Zhang, Pengli; Zhang, Yanhui; Li, Binbin; Zhang, Hailu; Lin, Haixia; Deng, Zongwu; Tan, Bo
• Is Part Of: Journal of peptide science. Volume 24:Number 4/5(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-03-27
• Subjects: cell tracking -- MRI -- MSC targeting peptide -- nanocluster -- self‐assembly; Peptides -- Periodicals; Peptides -- Periodicals; 572.65
• DOI: 10.1002/psc.3077
• Languages: English
• ISSNs: 1075-2617

Abstract

Abstract : A cyclic peptide CC9 that targets cell membrane of mesenchymal stem cells (MSCs) is coupled with Gd‐DOTA to yield a Gd‐DOTA‐CC9 complex as MRI contrast agent. It is used to label human MSCs (hMSCs) via electroporation. Electroporation‐labeling of hMSCs with Gd‐DOTA‐CC9 induces cell‐assembly of Gd‐DOTA‐CC9 nanoclusters in the cytoplasm, significantly promotes cell‐labeling efficacy and intracellular retention time of the agent. In vitro MRI of labeled hMSCs exhibits significant signal reduction under T 2 ‐weighted MRI, which can allow long‐term tracking of labeled cell transplants in in vivo migration. The labeling strategy is safe in cytotoxicity and differentiation potential. Abstract : A cyclic peptide CC9 that targets the cell membrane of mesenchymal stem cells is coupled with Gd‐DOTA to yield a Gd‐DOTA‐CC9 complex as MRI contrast agent. Labeling human mesenchymal stem cells with Gd‐DOTA‐CC9 via electroporation induces cell‐assembly of Gd‐DOTA‐CC9 nanoclusters in the cytoplasm and significantly promotes intracellular retention time of the agent. It allows long‐term tracking of labeled cell transplants under T 2 ‐weighted MRI in in vivo viability and migration.